

FACET BIOTECH CORP  
Form SC TO-T/A  
December 03, 2009  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Amendment No. 4  
to

**SCHEDULE TO**

**Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of  
the Securities Exchange Act of 1934**

**Facet Biotech Corporation**  
*(Name of Subject Company)*

**FBC Acquisition Corp.  
Biogen Idec Inc.**  
*(Names of Filing Persons Offerors)*

**Common Stock, Par Value \$0.01 Per Share**  
*(Title of Class of Securities)*

**30303Q103**  
*(Cusip Number of Class of Securities)*

**Susan H. Alexander, Esq.**  
**Executive Vice President, General Counsel and Secretary**  
**Biogen Idec Inc.**  
**14 Cambridge Center**  
**Cambridge, Massachusetts 02142**  
**Telephone: (617) 679-2000**  
*(Name, Address and Telephone Number of Person Authorized to Receive Notices  
and Communications on Behalf of Filing Persons)*

*Copies to:*

**Patricia A. Vlahakis, Esq.**  
**Wachtell, Lipton, Rosen & Katz**  
**51 West 52nd Street**  
**New York, New York 10019**  
**Telephone: (212) 403-1000**

**Calculation of Filing Fee**

**Transaction Valuation\***  
**\$449,901,200.00**

**Amount of Filing Fee**  
**\$25,104.49**

\* Estimated for purposes of calculating the amount of the filing fee only. The amount of the filing fee is calculated by multiplying the total transaction value by 0.00005580. The transaction value was calculated by adding the sum of (i) 25,067,740 shares of common stock, par value \$0.01 (Common Stock ), of Facet Biotech Corporation (the Company )

---

reported by the Company to be outstanding as of October 27, 2009, less 100 shares of Common Stock owned by Biogen Idec Inc., and multiplied by \$17.50 (the increased offer price per share), and (ii) 641,000 shares that may be subject to issuance pursuant to the exercise of stock options reported by the Company to be exercisable as of September 30, 2009, multiplied by \$17.50 (the increased offer price per share).

- Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$20,506.39.

Filing Party: Biogen Idec Inc./FBC Acquisition Corp.

Form or Registration No.: Schedule TO.

Date Filed: Sept. 21, 2009.

- Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- third-party tender offer subject to Rule 14d-1.  
 issuer tender offer subject to Rule 13e-4.  
 going-private transaction subject to Rule 13e-3.  
 amendment to Schedule 13D under Rule 13d-2.

Check the appropriate boxes below to designate any transactions to which the statement relates:

If applicable, check the appropriate box(es) below to designate the appropriate rule provisions relied upon:

- Rule 13e-4(i) (Cross-Border Issuer Tender Offer)  
 Rule 14d-1(d) (Cross-Border Third Party Tender Offer)
-

This Amendment No. 4 amends and supplements the Tender Offer Statement on Schedule TO (the Schedule TO ) initially filed with the Securities and Exchange Commission on September 21, 2009 by Biogen Idec Inc. (Biogen Idec ) and FBC Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Biogen Idec, and amended by Amendment No. 1 filed on September 22, 2009, Amendment No. 2 filed on October 7, 2009 and Amendment No. 3 filed on October 16, 2009.

The Schedule TO, as previously amended, relates to a tender offer by FBC Acquisition Corp. to purchase all outstanding shares of common stock, par value \$0.01 per share (the Common Stock ), of Facet Biotech Corporation, a Delaware corporation (the Company ), including the associated preferred stock purchase rights issued under the Rights Agreement, dated as of September 7, 2009, between the Company and Mellon Investor Services LLC, as Rights Agent (the Rights and, together with the Common Stock, the Shares ), for a purchase price of \$14.50 per Share, net to the seller in cash, without interest thereon (and less any applicable withholding taxes), upon the terms and subject to the conditions set forth in the offer to purchase dated September 21, 2009 (the Offer to Purchase ) and in the related letter of transmittal filed as exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Schedule TO.

All capitalized terms used in this Amendment No. 4 without definition have the meanings ascribed to them in the Schedule TO.

The items of the Schedule TO set forth below are hereby amended and supplemented as follows:

**Items 1 through 9 and Item 11.**

On December 3, 2009 Purchaser increased the price it is offering to pay per Share in the Offer to \$17.50 per Share, net to the seller in cash, without interest (and less any applicable withholding taxes). The Offer to Purchase attached as Exhibit (a)(1)(A) and the related Letter of Transmittal attached as Exhibit (a)(1)(B) to the Schedule TO are hereby amended (x) to replace all references to the \$14.50 price Purchaser was previously offering to pay per Share in the Offer with the increased price of \$17.50 per Share and (y) to reflect that the increased Offer price of \$17.50 per Share represents a premium of approximately 98% over the Company's closing stock price on September 3, 2009, the last full trading day before Biogen Idec publicly announced its proposal to acquire all of the outstanding Shares. The remaining terms and conditions of the Offer remain unchanged.

In connection with this increase of the Offer price, Biogen Idec issued a press release containing an open letter to Company stockholders, a copy of which is attached as Exhibit (a)(5)(5) to this Schedule TO.

**SIGNATURES**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 3, 2009

BIOGEN IDEC INC.

By: /s/ Robert A. Licht

Name: Robert A. Licht

Title: Senior Vice President

FBC ACQUISITION CORP.

By: /s/ Robert A. Licht

Name: Robert A. Licht

Title: Vice President and Assistant  
Secretary

**EXHIBIT INDEX**

- (a)(1)(A) Offer to Purchase dated September 21, 2009.\*
- (a)(1)(B) Letter of Transmittal.\*
- (a)(1)(C) Notice of Guaranteed Delivery.\*
- (a)(1)(D) Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.\*
- (a)(1)(E) Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.\*
- (a)(1)(F) IRS Form W-9 (Request for Taxpayer Identification Number and Certification), including instructions for completing the form.\*
- (a)(5)(1) Summary Advertisement, published September 21, 2009.\*
- (a)(5)(2) Press Release issued by Biogen Idec Inc. on September 21, 2009.\*
- (a)(5)(3) Presentation regarding proposed Biogen Idec Inc. Acquisition of Facet Biotech Corporation, dated September 2009.\*\*
- (a)(5)(4) Press release issued by Biogen Idec Inc. on October 16, 2009.\*\*\*
- (a)(5)(5) Press release issued by Biogen Idec Inc. on December 3, 2009.
- (b) None.
- (d) None.
- (g) None.
- (h) None.

\* Previously filed under cover of Schedule TO on September 21, 2009.

\*\* Previously filed under cover of Schedule TO on September 22, 2009.

\*\*\* Previously filed under cover of Schedule TO on October 16, 2009.